Developer docs
API playgroundTry for free, no card

Search company profiles

ERT Clinical

Full company profile

uuid003p85g

Namestring
ERT Clinical
Websiteurl
ert.com
Company typeenum
Private
Founded yearint
1977
Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
clinical trial technology, eClinical solutions, cardiac safety monitoring, electronic clinical outcomes, medical imaging core lab
Industry3 codes
1eCOA/ePRO/eDiary & Patient-Facing Data Collection
CodeHLACAOABPrimaryYes
2Regulatory Submissions & Clinical Content Management (eCTD/Publishing)
CodeHLACAOANPrimaryNo
3Site & Investigator Platforms (Site Payments, Feasibility, Activation)
CodeHLACAOAJPrimaryNo
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Trial Endpoint Technology
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Trial Endpoint Technology Services
TypeSubscription Recurring
Description

Provides clinical trial endpoint solutions including cardiac safety, eCOA, medical imaging, precision motion, and respiratory services to pharmaceutical companies, biotechs, and CROs across all trial phases.

clario.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

ERT Clinical (now operating as Clario, part of Thermo Fisher Scientific) provides clinical trial endpoint technology and evidence generation services spanning cardiac safety, electronic clinical outcome assessments (eCOA), medical imaging, precision motion (wearable sensors), and respiratory solutions. The platform is unified by cloud-native Trial Enablement software and supports site-based, hybrid, and decentralized clinical trials across all phases (Phase I through IV) for pharmaceutical sponsors, biotechs, and contract research organizations in over 100 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 70% of FDA and EMA new drug approvals since 2015 involved Clario's technology
+3 more records
Product overview1 text field

ERT Clinical (now Clario, part of Thermo Fisher Scientific) offers a unified platform of clinical trial endpoint technologies. The portfolio includes five core solution areas: Cardiac Solutions (ECG, arrhythmia, blood pressure monitoring), eCOA (electronic clinical outcome assessments for CNS, oncology, and patient-reported outcomes), Medical Imaging (core lab services with AI-powered redaction), Precision Motion (wearable sensor-based digital endpoints), and Respiratory Solutions (spirometry, oscillometry, lung sounds). These are unified through Trial Enablement software for eligibility, analytics, and document management. The platform supports site-based, hybrid, and fully decentralized clinical trials across Phase I through Phase III/IV, with AI capabilities integrated across multiple solutions.

Product and service6 records
1Cardiac Solutions
CategoryClinical Trial Endpoint Technology
Description

Cardiac safety and efficacy endpoint solutions for all clinical trial phases. Includes arrhythmia analysis, blood pressure services, ECG monitoring from site-based to decentralized clinical trials (DCT) and Phase I-IV, Phase I/TQT cardiac assessment, and regulatory consultation with statistical analysis. Built for pharmaceutical sponsors, biotechs, and CROs seeking regulatory-ready cardiac safety evidence.

2eCOA (Electronic Clinical Outcome Assessment)
CategoryClinical Trial Endpoint Technology
Description

Electronic clinical outcome assessment platform for capturing patient-, clinician-, and observer-reported outcomes across CNS, oncology, and other therapeutic areas. Includes eCOA Neuroscience, eCOA Swift for early-phase oncology, eCOA Rapid Start pre-validated assessments, eCOA Science Services, rater/participant/caregiver training, suicidal ideation monitoring with the exclusive self-reported eC-SSRS, and eCOA Rescue Studies for troubled trials.

3Medical Imaging
CategoryClinical Trial Endpoint Technology
Description

Comprehensive medical imaging core lab services for clinical trials, including AI-powered image redaction, an imaging platform supporting multiple modalities (CT, MRI, endoscopy), and secure submission workflows compliant with 21 CFR Part 11 and EU GDPR. Designed for sponsors needing regulatory-grade imaging evidence across therapeutic areas.

4Precision Motion
CategoryClinical Trial Endpoint Technology
Description

Wearable-sensor-based digital endpoint solution for measuring objective mobility outcomes in clinical trials, centered on the Opal V2R research-grade wearable sensor. Backed by more than 750 scientific publications and used for clinical and translational research applications across neurological, musculoskeletal, and other indications.

5Respiratory Solutions
CategoryClinical Trial Endpoint Technology
Description

Pulmonary function testing solutions for clinical trials, including site-based spirometry, virtual home spirometry, cough and lung sound assessment, diffusing capacity (DLCO) testing, oscillometry for small airway function, spirometry with ePROs, and AI-enabled spirometry insights. Built for respiratory clinical trial sponsors and healthcare providers.

6Trial Enablement
CategoryClinical Trial Platform Software
Description

Cloud-native clinical trial software platform for participant screening, eligibility data management, business intelligence and analytics, endpoint and safety risk reporting, data exchange, and source document management. Provides the unified data and workflow layer underlying the company's cardiac, eCOA, medical imaging, precision motion, and respiratory solutions.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Thermo Fisher Scientific
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Thermo Fisher Scientific completed acquisition of Clario Holdings Inc., enabling pharma and biotech customers to accelerate innovation with deeper clinical insights. The acquisition was announced in October 2025 and completed in 2026, making Clario part of Thermo Fisher Scientific.

Expansion highlight5 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A8 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ERT Clinical

Clinical Trial Endpoint Technologyert.com

ERT Clinical firmographics

Firmographics
Name
ERT Clinical
Website
https://ert.com
Company type
Private
Founded year
1977
Operating status
Acquired
Headcount range
1,001–5,000 employees
Ownership category
akta.pro rank

ERT Clinical industry classification

Industry
Product category
Clinical Trial Endpoint Technology
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB)
akta.pro secondary industries
Regulatory Submissions & Clinical Content Management (eCTD/Publishing) (HLACAOAN), Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ)

Keywords

  • Clinical trial technology
  • EClinical solutions
  • Cardiac safety monitoring
  • Electronic clinical outcomes
  • Medical imaging core lab

Where ERT Clinical is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Markets served

ERT Clinical business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Clinical Trial Endpoint Technology Services: Provides clinical trial endpoint solutions including cardiac safety, eCOA, medical imaging, precision motion, and respiratory services to pharmaceutical companies, biotechs, and CROs across all trial phases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

ERT Clinical product offering

Product offering

Core offering

ERT Clinical (now operating as Clario, part of Thermo Fisher Scientific) provides clinical trial endpoint technology and evidence generation services spanning cardiac safety, electronic clinical outcome assessments (eCOA), medical imaging, precision motion (wearable sensors), and respiratory solutions. The platform is unified by cloud-native Trial Enablement software and supports site-based, hybrid, and decentralized clinical trials across all phases (Phase I through IV) for pharmaceutical sponsors, biotechs, and contract research organizations in over 100 countries.

Product overview

ERT Clinical (now Clario, part of Thermo Fisher Scientific) offers a unified platform of clinical trial endpoint technologies. The portfolio includes five core solution areas: Cardiac Solutions (ECG, arrhythmia, blood pressure monitoring), eCOA (electronic clinical outcome assessments for CNS, oncology, and patient-reported outcomes), Medical Imaging (core lab services with AI-powered redaction), Precision Motion (wearable sensor-based digital endpoints), and Respiratory Solutions (spirometry, oscillometry, lung sounds). These are unified through Trial Enablement software for eligibility, analytics, and document management. The platform supports site-based, hybrid, and fully decentralized clinical trials across Phase I through Phase III/IV, with AI capabilities integrated across multiple solutions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cardiac Solutions Cardiac safety and efficacy endpoint solutions for all clinical trial phases. Includes arrhythmia analysis, blood pressure services, ECG monitoring from site-based to decentralized clinical trials (DCT) and Phase I-IV, Phase I/TQT cardiac assessment, and regulatory consultation with statistical analysis. Built for pharmaceutical sponsors, biotechs, and CROs seeking regulatory-ready cardiac safety evidence.
  • eCOA (Electronic Clinical Outcome Assessment) Electronic clinical outcome assessment platform for capturing patient-, clinician-, and observer-reported outcomes across CNS, oncology, and other therapeutic areas. Includes eCOA Neuroscience, eCOA Swift for early-phase oncology, eCOA Rapid Start pre-validated assessments, eCOA Science Services, rater/participant/caregiver training, suicidal ideation monitoring with the exclusive self-reported eC-SSRS, and eCOA Rescue Studies for troubled trials.
  • Medical Imaging Comprehensive medical imaging core lab services for clinical trials, including AI-powered image redaction, an imaging platform supporting multiple modalities (CT, MRI, endoscopy), and secure submission workflows compliant with 21 CFR Part 11 and EU GDPR. Designed for sponsors needing regulatory-grade imaging evidence across therapeutic areas.
  • Precision Motion Wearable-sensor-based digital endpoint solution for measuring objective mobility outcomes in clinical trials, centered on the Opal V2R research-grade wearable sensor. Backed by more than 750 scientific publications and used for clinical and translational research applications across neurological, musculoskeletal, and other indications.
  • Respiratory Solutions Pulmonary function testing solutions for clinical trials, including site-based spirometry, virtual home spirometry, cough and lung sound assessment, diffusing capacity (DLCO) testing, oscillometry for small airway function, spirometry with ePROs, and AI-enabled spirometry insights. Built for respiratory clinical trial sponsors and healthcare providers.
  • Trial Enablement Cloud-native clinical trial software platform for participant screening, eligibility data management, business intelligence and analytics, endpoint and safety risk reporting, data exchange, and source document management. Provides the unified data and workflow layer underlying the company's cardiac, eCOA, medical imaging, precision motion, and respiratory solutions.

Quantifiable outcome

  • 70% of FDA and EMA new drug approvals since 2015 involved Clario's technology
  • +3 more outcomes

Companies that use ERT Clinical

Customer profile

Segments5 records

Ideal customer profiles3 records

ERT Clinical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature8 records

ERT Clinical partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Thermo Fisher ScientificflagshipStrategic or Co-development Partner · 1 January 2026Thermo Fisher Scientific completed acquisition of Clario Holdings Inc., enabling pharma and biotech customers to accelerate innovation with deeper clinical insights. The acquisition was announced in October 2025 and completed in 2026, making Clario part of Thermo Fisher Scientific.

Scale indicators7 records

Expansion highlights5 records

ERT Clinical competitors and assessment

Company assessment

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

ERT Clinical social profiles

Digital presence

ERT Clinical compliance and trust

Trust signal

Compliance3 records

ERT Clinical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ERT Clinical leadership team

Management profile

Number of profiles

Profiles18 records

ERT Clinical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ERT Clinical M&A and investment

M&A and investment

M&A8 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ERT Clinical

What does ERT Clinical do?

ERT Clinical (now operating as Clario, part of Thermo Fisher Scientific) provides clinical trial endpoint technology and evidence generation services spanning cardiac safety, electronic clinical outcome assessments (eCOA), medical imaging, precision motion (wearable sensors), and respiratory solutions. The platform is unified by cloud-native Trial Enablement software and supports site-based, hybrid, and decentralized clinical trials across all phases (Phase I through IV) for pharmaceutical sponsors, biotechs, and contract research organizations in over 100 countries.

Is ERT Clinical a public or private company?

ERT Clinical is a private company. It is classified as corporate owned and is currently acquired.

When was ERT Clinical founded?

ERT Clinical was founded in 1977. It employs 1,001 to 5,000 people.

Where is ERT Clinical based?

ERT Clinical is headquartered in Philadelphia, United States, in the North America region.

How does ERT Clinical make money?

One revenue line is on record: clinical Trial Endpoint Technology Services.

Does ERT Clinical have an API?

No public API is recorded for ERT Clinical.

What industry is ERT Clinical in?

ERT Clinical's product category is Clinical Trial Endpoint Technology. Its primary akta.pro industry code is HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection, with a secondary code of HLACAOAN, Regulatory Submissions & Clinical Content Management (eCTD/Publishing). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comMarket Structure, Emerging Trends, and Key Player Analysis of Electronic Clinical Outcome Assessment SolutionsThe electronic clinical outcome assessment (eCOA) solutions market is projected to grow to $3.62 billion by 2030 at a compound annual growth rate of 13.1%, driven by decentralized clinical trials, AI-powered data analytics, and patient-centric trial designs. Signant Health, a US-based healthcare technology firm, acquired DSG Inc. in July 2023 to strengthen its eClinical solution offerings and broaden its technological capabilities for both traditional and decentralized clinical trials. Key players in the market include IQVIA Holdings Inc., ERT Clinical, OmniComm Systems Inc., Parexel International Corporation, Veeva Systems Inc., and Medidata Solutions Inc.PR Newswire$11.4 Billion Worldwide Cognitive Assessment and Training Industry to 2027 - Featuring CRF Bracket, CogniFit and ERT Clinical Among OthersResearch and Markets has published a report projecting the global cognitive assessment and training market to grow from US$3.0 billion in 2021 to US$11.4 billion by 2027, representing a compound annual growth rate of 24.92%. The market is being driven by a growing geriatric population, increasing dementia prevalence, rising awareness of brain fitness, and technological advancements such as computerized cognitive assessments with automated scoring. Key players identified in the competitive landscape include CRF Bracket, CogniFit, ERT Clinical, Cambridge Cognition Ltd., Cogstate Ltd., and Quest Diagnostics Inc., among others.PR NewswireWorldwide Cognitive Assessment and Training Industry to 2026 - Players Include CRF Bracket, Brain Resource and ERT Clinical Among OthersResearch and Markets has added a new report titled "Cognitive Assessment and Training Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" to its offerings. The report projects the global market will grow at a CAGR of approximately 22% during the forecast period, driven by an aging population and increasing awareness of brain health. It provides detailed analysis of key industry players, regional markets, and competitive landscapes.Clinical LeaderERT Offers First Patient-Administered ECG Assessment For Continuation Of Clinical Trials During COVID-19ERT announced a partnership with AliveCor to use the FDA-cleared KardiaMobile 6L device for patient-administered ECG data in clinical trials. The device captures 6-lead data without electrodes, and ERT's cardiologists will read the data to ensure patient safety. The partnership aims to allow trials to continue during the COVID-19 pandemic.GlobeNewswireElectronic Clinical Outcome Assessment (eCOA) Market Emerging Technology, Investor Analysis and Worldwide Forecast till 2027- Oracle, Parexel International Corporation, ERT Clinical, Bioclinica, IBM CData Bridge Market Research forecasts the global electronic clinical outcome assessment (eCOA) market to grow at a 15.5% CAGR from 2020 to 2027, reaching USD 2,630.26 million by 2027. The report profiles key players including Oracle, Parexel, and IBM, and segments the market by product, approach, and end user.FinSMEsERT Acquires iCardiac TechnologiesERT acquired iCardiac Technologies, a provider of centralized cardiac safety and respiratory clinical trial services. The deal amount was not disclosed, but iCardiac serves eight of the top 10 global pharmaceutical companies. Alex Zapesochny will lead ERT's Cardiac Safety business.